Skip to main content
Realcan Pharmaceutical Group Co.,Ltd. logo

Realcan Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 002589 ISIN · CNE1000013X5 LEI · 300300YI5IV3FBRRSJ48 Shenzhen Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,678 across all filing types
Latest filing 2019-09-22 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 002589

About Realcan Pharmaceutical Group Co.,Ltd.

https://www.realcan.cn

Realcan Pharmaceutical Group Co., Ltd. specializes in the distribution of pharmaceutical products, medical devices, and healthcare consumables. The company operates an extensive supply chain network, providing integrated logistics and distribution services primarily to medical institutions and healthcare providers. Its core operations include the procurement, storage, and delivery of a wide range of medical supplies, supported by advanced information management systems and cold-chain logistics capabilities. Realcan also offers value-added services such as hospital supply chain optimization, third-party logistics, and financial solutions tailored to the healthcare industry. By focusing on a direct-to-hospital distribution model, the company aims to enhance the efficiency of medical supply procurement and ensure the timely delivery of critical healthcare products.

Recent filings

Filing Released Lang Actions
独立董事提名人声明（一）
Board/Management Information Classification · 95% confidence The document is a formal statement from a nominator regarding the nomination of an independent director candidate for the company's board. It includes detailed declarations about the candidate's qualifications, compliance with regulatory requirements, and independence criteria. There is no financial data, earnings information, or report publication mentioned. The content focuses on board/management information, specifically the nomination of a board member. Therefore, the document fits best under the category of Board/Management Information (MANG). The document length and detail support this classification with high confidence.
2019-09-22 Chinese
独立董事提名人声明（三）
Board/Management Information Classification · 95% confidence The document is a formal public statement from a nominator (瑞康医药集团股份有限公司) regarding the nomination of an individual (武滨) as an independent director candidate for the company's fourth board of directors. It includes detailed declarations about the nominee's qualifications, compliance with various regulatory requirements, and independence criteria. The content is focused on board/management information, specifically the nomination of a board member, rather than financial results, audit, or other report types. There is no indication that this is a report or announcement of voting results, nor is it a general regulatory filing or remuneration report. The document is a nomination statement related to board composition, which fits best under Board/Management Information (MANG). The document length (6373 characters) and detailed content support this classification with high confidence.
2019-09-22 Chinese
关于终止部分募集资金投资项目的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company regarding the termination of part of its fundraising investment projects and the reallocation of remaining funds to supplement working capital. It details the original fundraising project, the reasons for termination, and the approvals from the board and independent directors. The document is relatively short (3428 characters) and does not contain financial statements or detailed financial data. It is an announcement about changes in the use of raised capital rather than a full financial report or audit. Therefore, it fits best under Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes.
2019-09-22 Chinese
关于为全资及控股子公司提供担保及对公司已担保额度进行减少的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from 瑞康医药集团股份有限公司 regarding guarantees provided for its wholly-owned and controlled subsidiaries, including adjustments to guarantee limits. It includes specific financial figures, lists of subsidiaries, and opinions from the board, supervisory committee, and independent directors. The content focuses on corporate financing activities related to guarantees and credit facilities, not on financial results, management changes, or legal proceedings. There is no indication that this is a full financial report, audit report, or earnings release. The document is not a brief announcement or a certification but a substantive update on capital/financing matters. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length (over 14,000 characters) and detailed financial data support this classification with high confidence.
2019-09-22 Chinese
第三届董事会第二十六次会议决议的公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 26th meeting of the third board of directors of 瑞康医药集团股份有限公司 (Ruikang Pharmaceutical Group Co., Ltd.). It includes multiple agenda items such as changes in company type, guarantees for subsidiaries, termination of investment projects, nomination of non-independent and independent directors for the fourth board, issuance of asset-backed securities, issuance of overseas debt financing instruments, and the proposal to convene the fifth extraordinary general meeting of shareholders in 2019. The document also contains detailed biographies of the nominated directors. The content focuses on board decisions, director nominations, and financing plans, with voting results and references to further shareholder approval. There are no financial statements or quarterly/yearly financial results presented. The document is not a full annual or interim report, nor an earnings release or audit report. It is not a proxy solicitation or voting results declaration, but rather a board meeting resolution announcement including management and board changes and financing plans. Given the emphasis on board meeting resolutions and director nominations, the most appropriate classification is Board/Management Information (MANG). The document length (over 11,000 characters) and detailed content confirm it is not a brief announcement or a report publication announcement.
2019-09-22 Chinese
独立董事对第三届董事会第二十六次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on various proposals related to the company's board meeting, including guarantees for subsidiaries, termination of fundraising projects, nomination of board candidates, and support for asset-backed plans. It references compliance with laws and regulations, and the intention to submit these matters to the shareholders' meeting for approval. The document is not a full financial report, earnings release, or audit report. It is a formal opinion related to board and management matters, specifically about board nominations and governance-related proposals. Therefore, it fits best under Board/Management Information (MANG). The document length is 2517 characters, which is relatively short and focused on management and board issues rather than financial data or regulatory filings.
2019-09-22 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.